PMID- 37787903
OWN - NLM
STAT- MEDLINE
DCOM- 20240109
LR  - 20240130
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 43
IP  - 1
DP  - 2024 Jan
TI  - Earlier clinical response predicts low rates of radiographic progression in 
      biologic-naive patients with active psoriatic arthritis receiving guselkumab 
      treatment.
PG  - 241-249
LID - 10.1007/s10067-023-06745-y [doi]
AB  - OBJECTIVE: Assess relationship between earlier clinical improvement and 
      radiographic progression (RP) over 2 years in guselkumab-treated patients with 
      active psoriatic arthritis (PsA). METHOD: Post hoc analyses combined data from 
      DISCOVER-2 biologic-naive adults with active PsA randomized to either guselkumab 
      100 mg every 4 weeks (Q4W) or guselkumab at W0, W4, then Q8W. Correlations 
      (Spearman's coefficient) between baseline disease parameters and total 
      PsA-modified van der Heijde-Sharp (vdH-S) score were examined. Repeated-measures 
      mixed models, adjusted for known RP risk factors, assessed the relationship 
      between Disease Activity Index in PsA (DAPSA) improvement, DAPSA improvement 
      exceeding the median or the minimal clinically important difference (MCID), or 
      DAPSA low disease activity (LDA) at W8 and RP rate, assessed by change from 
      baseline in vdH-S score through W100. RESULTS: Baseline age, PsA duration, CRP 
      level, and swollen joint count, but not psoriasis duration/severity, weakly 
      correlated with baseline vdH-S score. Elevated baseline CRP (parameter estimate 
      [beta] = 0.17-0.18, p < 0.03) and vdH-S score (beta = 0.02, p < 0.0001) significantly 
      associated with greater RP through W100. Greater improvement in DAPSA (beta = -0.03, 
      p = 0.0096), achievement of DAPSA improvement > median (least squares mean [LSM] 
      difference: -0.66, p = 0.0405) or > MCID (-0.67, p = 0.0610), or DAPSA LDA 
      (-1.44, p = 0.0151) by W8 with guselkumab significantly associated with less RP 
      through W100. The effect of W8 DAPSA LDA on future RP was strengthened over time 
      among achievers vs. non-achievers (LSM difference enhanced from -1.05 
      [p = 0.0267] at W52 to -1.84 [p = 0.0154] at W100). CONCLUSIONS: In 
      guselkumab-treated patients with active PsA, earlier improvement in joint 
      symptoms significantly associated with lower RP rates through 2 years, indicating 
      blockade of the IL-23 pathway may modify long-term disease course and prevent 
      further joint damage. Key Points * Greater improvement in DAPSA at Week 8 of 
      guselkumab treatment was significantly associated with less progression of 
      structural joint damage at 2 years in patients with active psoriatic arthritis 
      (PsA). * Early control of peripheral joint disease activity with blockade of the 
      IL-23 pathway may modify long-term PsA trajectory and prevent further joint 
      damage.
CI  - (c) 2023. The Author(s).
FAU - Mease, Philip J
AU  - Mease PJ
AUID- ORCID: 0000-0002-6620-0457
AD  - Swedish Medical Center/Providence St. Joseph Health and University of Washington, 
      Seattle, WA, USA. pmease@philipmease.com.
FAU - Gottlieb, Alice B
AU  - Gottlieb AB
AUID- ORCID: 0000-0002-2927-8618
AD  - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Ogdie, Alexis
AU  - Ogdie A
AUID- ORCID: 0000-0002-4639-0775
AD  - Division of Rheumatology, University of Pennsylvania School of Medicine, 
      Philadelphia, PA, USA.
FAU - McInnes, Iain B
AU  - McInnes IB
AUID- ORCID: 0000-0002-6462-4280
AD  - College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, 
      UK.
FAU - Chakravarty, Soumya D
AU  - Chakravarty SD
AUID- ORCID: 0000-0001-7957-838X
AD  - Janssen Scientific Affairs, LLC, Horsham, PA, USA.
AD  - Drexel University College of Medicine, Philadelphia, PA, USA.
FAU - Rampakakis, Emmanouil
AU  - Rampakakis E
AUID- ORCID: 0000-0002-7427-8246
AD  - Department of Pediatrics, McGill University, Montreal, QC, Canada.
AD  - JSS Medical Research, Montreal, Canada.
FAU - Kollmeier, Alexa
AU  - Kollmeier A
AUID- ORCID: 0000-0002-2059-7866
AD  - Immunology, Janssen Research & Development, LLC, San Diego, CA, USA.
FAU - Xu, Xie L
AU  - Xu XL
AD  - Immunology, Janssen Research & Development, LLC, San Diego, CA, USA.
FAU - Shawi, May
AU  - Shawi M
AUID- ORCID: 0000-0001-6005-3938
AD  - Immunology, Janssen Research & Development, LLC, Titusville, NJ, USA.
FAU - Lavie, Frederic
AU  - Lavie F
AUID- ORCID: 0000-0002-5213-257X
AD  - Janssen Cilag Global Medial Affairs, Immunology Global Medical Affairs, Issy Les 
      Moulineaux, France.
FAU - Kishimoto, Mitsumasa
AU  - Kishimoto M
AUID- ORCID: 0000-0002-4007-1589
AD  - Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 
      Mitaka, Tokyo, Japan.
FAU - Rahman, Proton
AU  - Rahman P
AUID- ORCID: 0000-0002-4521-2029
AD  - Discipline of Medicine, Division of Rheumatology, Memorial University of 
      Newfoundland, St. John's, NF, Canada.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20231003
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 089658A12D (guselkumab)
RN  - 0 (Antirheumatic Agents)
RN  - 103771-11-5 (N-(8-aminohexyl)-5-iodonaphthalene-1-sulfonamide)
RN  - 0 (Biological Products)
RN  - 0 (Interleukin-23)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Arthritis, Psoriatic/diagnostic imaging/drug therapy
MH  - *Antirheumatic Agents/therapeutic use
MH  - Treatment Outcome
MH  - Severity of Illness Index
MH  - *Biological Products/therapeutic use
MH  - Interleukin-23
PMC - PMC10774160
OTO - NOTNLM
OT  - DAPSA
OT  - Guselkumab
OT  - Psoriatic arthritis
OT  - Radiographic progression
OT  - Structural joint damage
OT  - vdH-S score
COIS- PJM has received research support, consulting fees, and/or speaker bureau support 
      from AbbVie, Acelyrin, Aclaris, Amgen, Bristol Myers Squibb, Eli Lilly, 
      Galapagos, Gilead, Inmagene, Janssen, MoonLake Immunotherapeutics, Novartis, 
      Pfizer, Sun Pharma, UCB, Ventyx, and Xinthera. ABG has received honoraria as an 
      advisory board member and consultant for Amgen, AnaptypsBio, Avotres 
      Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Eli 
      Lilly, Janssen, Novartis, Sanofi, UCB, and Xbiotech, and has received 
      research/educational grants from AnaptypsBio, Bristol Myers Squibb, Moonlake 
      Immunotherapeutics AG, Novartis, and UCB (all paid to Mount Sinai School of 
      Medicine). AO has received consulting fees from AbbVie, Amgen, Bristol Myers 
      Squibb, Celgene, CorEvitas, Eli Lilly, Gilead, Happify Health, Janssen, Novartis, 
      Pfizer, and UCB; grant/research support to the University of Pennsylvania from 
      AbbVie, Janssen, Novartis, and Pfizer, and to Forward from Amgen. Her husband has 
      received royalties from Novartis. IBM has received consulting fees from AbbVie, 
      Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, 
      Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; 
      grant/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, 
      GlaxoSmithKline, Janssen, Novartis, Roche, and UCB; and is a shareholder of 
      Causeway Therapeutics, and Evelo Compugen, SDC is an employee of Janssen 
      Scientific Affairs, LLC and owns stock or stock options in Johnson & Johnson, of 
      which Janssen Scientific Affairs, LLC is a wholly owned subsidiary. ER is a 
      consultant of Janssen and an employee of JSS Medical Research. AK is an employee 
      of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & 
      Johnson, and owns stocks in Johnson & Johnson. XLX is an employee of Janssen 
      Research & Development. MS is an employee of Janssen Research & Development and 
      owns stock or stock options in Johnson & Johnson. FL is an employee of Immunology 
      Global Medical Affairs, Janssen Pharmaceutical Companies and owns stock in 
      Johnson & Johnson. MK has received consulting fees and/or speakers fees 
      from AbbVie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, Bristol Myers 
      Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Novartis, 
      Pfizer, Tanabe-Mitsubishi, and UCB. PR has received consulting fees from AbbVie, 
      Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, 
      Pfizer, and UCB; travel support from Janssen; and grants from Janssen, and 
      Novartis.
EDAT- 2023/10/03 12:45
MHDA- 2024/01/09 06:42
PMCR- 2023/10/03
CRDT- 2023/10/03 11:10
PHST- 2023/06/29 00:00 [received]
PHST- 2023/08/18 00:00 [accepted]
PHST- 2023/08/17 00:00 [revised]
PHST- 2024/01/09 06:42 [medline]
PHST- 2023/10/03 12:45 [pubmed]
PHST- 2023/10/03 11:10 [entrez]
PHST- 2023/10/03 00:00 [pmc-release]
AID - 10.1007/s10067-023-06745-y [pii]
AID - 6745 [pii]
AID - 10.1007/s10067-023-06745-y [doi]
PST - ppublish
SO  - Clin Rheumatol. 2024 Jan;43(1):241-249. doi: 10.1007/s10067-023-06745-y. Epub 
      2023 Oct 3.